High affinity site-specific O-GlcNAc antibodies, to date, have eluded production using the traditional approaches to generate antibodies (Abs).  This difficulty may result from O-GlcNAc modified epitopes being self-antigens, thus, tolerated by the immune system, and combined with the relatively weak carbohydrates-protein interaction that complicates antibody maturation.  GlycoScientific has developed a novel immunization strategy to overcome these issues.

At GlycoScientific we develop site-specific antibodies that can be used as tools in the elucidation of the role that O-GlcNAc plays in epigenetics and in chronic human disease including diabetes, cardiovascular disease, neurodegenerative disorders, and cancer.

The technology we use is highly efficient to generate site-specific O-GlcNAc antibodies that have a strong preference towards the modified species over the non-modified form and have high specificity to the correct amino acid sequence.  Furthermore, our antibodies are capable of capturing the correct target via immunoprecipitation and can be used with CHIP-sequencing.